Skip to content
Menu

Kazia Therapeutics Limited KZIA

Full chart Compare
Set alert

Price alert · KZIA

All alert types
5.47 USD -0.13 (-2.32%)

As ofNov 17, 2026, 1:57 PM EST

5.26 Day range 5.85
4.86 52-week range 17.40
YTD
-20.61%
1 year
-10.03%
Market cap
62.51M
Revenue (ttm)
560
EPS (ttm)
-6.85
Shares out
4.35M
YTD return
-20.61%
1-year return
-10.03%
50-day average
4.90
Volume
375.63K
Avg volume
286.36K
Open
5.61
Previous close
5.60
Day's range
5.26 – 5.85
52-week range
4.86 – 17.40
Beta
2.08

5D -2.06 (-27.28%)

67WedThuFriMonTue5.49

Key statistics

200-day average
3.80
Enterprise value
1.20B
Price / sales
23096.84
Price / book
1.49
Free cash flow
-6.57M
Total cash
3.56M
Total debt
359.30K
Return on equity
-186.37%
Short % of float
1.68%

Fundamental scorecard

7 of 25 checks passed on KZIA’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Dec 31, 2025.

Financials — quick view

All financials
KZIA Revenue — annual 1.83M
KZIA Net income — annual -20.70M
KZIA EPS — annual -3.78

Upgrades / downgrades

KZIA analyst upgrades and downgrades
DateFirmActionFromTo
Jul 12, 2024HC Wainwright & Co.reitBuyBuy
Apr 11, 2023HC Wainwright & Co.upNeutralBuy
Aug 2, 2022Maxim GroupdownBuyHold
Aug 2, 2022HC Wainwright & Co.downBuyNeutral
Oct 14, 2021Maxim Groupinit—Buy
Jan 5, 2021HC Wainwright & Co.init—Buy

About Kazia Therapeutics Limited

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Sector
Healthcare
Industry
Biotechnology
Country
Australia

News

Your note

Sign in to keep a note on KZIA — it syncs with the Stock Master app.

Institution ownership

KZIA institution ownership
Holder% heldSharesValueReported
MAI Capital Management3.13%136,389405.07KSep 29, 2024
UBS Group AG0.57%24,94574.09KSep 29, 2024
Morgan Stanley0.51%22,02665.42KSep 29, 2024
Captrust Financial Advisors0.35%15,26545.34KSep 29, 2024
Citadel Advisors Llc0.14%6,04817.96KSep 29, 2024
Jane Street Group, LLC0.11%4,61113.69KSep 29, 2024

Fund ownership

KZIA fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.03%1,4784.39KOct 30, 2024